Blaze is a privately held biotechnology company dedicated to improving the lives of cancer patients, starting with kids undergoing brain cancer surgery.
Location: United States, Washington, Seattle
Total raised: $22.5M
Investors 2
| Date | Name | Website |
| - | Willamette... | willamette... |
| - | Keiretsu F... | keiretsufo... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.12.2013 | Series B | $9M | - |
| 22.02.2013 | Series A | $8.5M | - |
| 08.06.2012 | Series A | $5M | - |
Mentions in press and media 19
| Date | Title | Description |
| 26.02.2019 | How scorpion venom helps improve brain cancer surgery in children by making tumors glow | Blaze Bioscience’s “Tumor Paint” is a synthetic version of a peptide originally found in the Israeli deathstalker scorpion. (Alastair Rae Photo via Flickr) Seattle biotech company Blaze Bioscience has raised $5 million in funding as it purs... |
| 11.10.2017 | Seattle Biotech Blaze Bioscience Adds $16M for Clinical Trial Work | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Blaze Bioscience, a Seattle-based biotech that’s developing “tumor paint” to help surgeons differentiate healthy tissue from tumors that should be removed, has raised a $16.1 ... |
| 09.01.2014 | Avelas’ luminous mapping technology to guide breast cancer surgery attracts $6.85M | Avalon Ventures led the round and new investors Torrey Pines Investment, WuXi AppTec and an unnamed investor also took part. One advantage of Avelas’ platform is that it can help surgeons evaluate tumor samples in real-time. According to th... |
| 23.12.2013 | Deals of the Year: The top 28 venture capital investments we tracked in 2013 | Venture capital investing in Washington state started out with a whimper in 2013, but it is ending with a bang. After the slow start, as evidenced by the chart above from CB Insights in which just $100 million was invested in the first quar... |
| 03.12.2013 | Tumor paint startup Blaze Bioscience raises $9M to help surgeons pinpoint cancer cells | Blaze Bioscience has raised $9 million in fresh funding from individual investors, money that the Seattle spinoff of the Fred Hutchinson Cancer Research Center will use to continue development on an innovative product dubbed Tumor Paint. To... |
| 03.12.2013 | Blaze Bioscience Raises $9M in Series B Financing | Blaze Bioscience, Inc., a Seattle, WA-based biotechnology company, raised $9m in Series B financing. The round, which brought total funds since inception to $19m, was raised from new and existing individual investors. The company intends to... |
| 03.12.2013 | Imaging agent that ‘paints’ tumor cells for more precise removal nets $9M for clinical trials | In the video above, Blaze Bioscience’s scientific founder, Dr. James Olson, describes how the scorpion-derived protein “happens to bind to cancer cells, but not to normal tissues.” A team from the Fred Hutchinson Cancer Research Center and ... |
| 03.12.2013 | Tumor Paint helps doctors cut the cancers, not healthy tissue, from kids’ brains | Jim Olson has spent far too many years explaining to parents why he removed a healthy part of their child’s brain, in order to surgically remove the tumor. On an MRI scan, cancer is easy enough to spot. But during surgery, these cells can l... |
| 22.02.2013 | Blaze Bioscience Grabs $8.5M Series A | SEATTLE, WA, Biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, today announced the completion of a Series A financing totaling $8.5 million. >> Click here for more funding da... |
| 22.02.2013 | Blaze Bioscience raises $8.5M to help surgeons pinpoint cancer cells with ‘tumor paint’ | Jim Olson Seattle biotechnology startup Blaze Bioscience has raised $8.5 million to continue developing technologies that are designed to help surgeons more easily identify cancer cells in the body. Total funding in the company, with operat... |
Show more